Skip to content

Effect of Zhisou Powder on Pulmonary Function and Inflammatory Markers in Patients with Small Airway Disease.

Effect of Zhisou Powder on Pulmonary Function and Inflammatory Markers in Patients with Small Airway Disease.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040412
Enrollment
Unknown
Registered
2020-11-28
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Airway Disease

Interventions

Sponsors

SHANTOU CENTRAL HOSPITAL
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. More than 18 years old, male or female; 2. Meet the pulmmonary function criteria for small airway disease: MMEF, FEF50, FEF75 decreased, and more than 2 indicators were lower than 65% of the expected value; 3. Willing to take oral Chinese medicine treatment; 4. Able to communicate and write in language or text; 5. Sign the informed consent form voluntarily.

Exclusion criteria

Exclusion criteria: 1. There are major diseases, such as lung malignant tumors, heart failure, renal failure, dementia, epilepsy, active tuberculosis, etc.; 2. Using respiratory drugs in past weeks,such as inhaled corticosteroids, anticholinergic drugs, ß2 receptor agonists, leukotriene receptor antagonists, etc.; 3. Currently in acute exacerbation of respiratory diseases, such as acute exacerbation of chronic obstructive pulmonary disease, acute exacerbation of asthma, etc.; 4. Acute cardiovascular and cerebrovascular events (stroke, transient ischemic attack, acute coronary syndrome) in the past 3 months; 5. History of malignant tumors that are not completely cured; 6. Mental illness, drug addiction or alcoholism; 7. Lactation, pregnancy, or planned pregnancy in the near future; 8. History of allergy to Chinese medicinal materials, or unwillingness to take Chinese medicinal preparations; 9. Those who are not expected to cooperate or are not suitable for follow-up; 10. The informed consent is not signed.

Design outcomes

Primary

MeasureTime frame
Pulmonary Function Test;

Secondary

MeasureTime frame
Respiratory Questionnaire;Induced Sputum;Inflammation Biomarkers;

Countries

China

Contacts

Public ContactZHENG JINZHEN

SHANTOU CENTRAL HOSPITAL

115578232@qq.com+86 13929609270

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026